PDCD1 and neoplasm: It has been reported previously that TYRO3 expression was higher in the patients with lung cancer who were resistant to nivolumab, pembrolizumab, and atezolizumab than that in the patients whose tumor progression was controlled by anti-PD-1/PD-L1 therapy.